Dr. Zhang on frontline treatment selection factors in metastatic kidney cancer

Video

“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.

Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses factors she uses in the clinic to decide among the evolving treatment options in the frontline setting for patients with metastatic renal cell carcinoma.

Related Videos
Nirmish Singla, MD, MSc, answers a question during a Zoom video interview
Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
Nirmish Singla, MD, MSc, answers a question during a Zoom video interview
Carlos Muñoz-Lopez and Dr. Steven Campbell in an interview with Urology Times
Carlos Muñoz-Lopez and Dr. Steven Campbell in an interview with Urology Times
Dr. Michael Stifelman in an interview with Urology Times
Teona Iarajuli in an interview with Urology Times
hospital corridor
Related Content
© 2023 MJH Life Sciences

All rights reserved.